This piece from Judd Legum delivers a forensic accounting of a biotech boom that left public pension funds bleeding while its architect walked away with a quarter-billion dollars. The central revelation isn't just that a failed drug was marketed aggressively; it is the specific, documented role of the founder's mother in re-engineering clinical data to manufacture a false narrative of success. For voters watching a billionaire candidate claim his business acumen is a blueprint for governance, Legum's reporting exposes a disturbing disconnect between the public promise of medical breakthroughs and the private mechanics of financial extraction.
The Architecture of a False Hope
Legum begins by dismantling the origin story of Axovant, a company that took a drug repeatedly rejected by major pharmaceutical giants and repackaged it as a miracle cure. The author notes that the drug, intepirdine, had already "failed multiple Phase 2 clinical trials" before being acquired for a mere $5 million—a figure Legum describes as "lunch money" compared to industry standards. The core of the argument rests on the sudden turnaround of these failure statistics once the drug entered the Ramaswamy sphere.
Judd Legum writes, "Axovant then hired Ramaswamy's mother, who, despite lacking relevant research experience, helped massage data from old clinical trials to make the drug appear more promising." This is the piece's most damning allegation: that the scientific validation required to launch a $1.4 billion public offering was not generated by new discovery, but by the selective editing of old, negative results. The author highlights that Geetha Ramaswamy's previous roles were in management and recruiting, not in conducting clinical trials, yet she was credited with co-authoring the pivotal analyses that secured investor confidence.
The commentary here is sharp because it focuses on the methodology of deception rather than just the outcome. Legum details how the team employed a "responder analysis," a statistical technique that divides patients into binary "pass-or-fail" categories rather than measuring continuous cognitive decline. This approach, Legum notes, was criticized by experts in the journal Alzheimer's & Dementia for increasing the risk of "causal fraud." The author effectively uses this technical detail to show that the fraud wasn't a matter of opinion, but a deliberate manipulation of statistical power to hide the drug's ineffectiveness.
"Statistical approaches that rely on a dichotomized binary outcome... result in a loss of information and reduced statistical power, increasing the risk of false positives and negatives."
Legum further exposes the use of "completer analysis," which discarded data from the 30% of patients who dropped out of the trial. By excluding these dropouts, the company could claim a "statistically significant benefit" where none existed in the full dataset. The author points out that this method was flagged by biostatistician Thomas R. Fleming as "simplistic" and prone to bias. This framing is crucial: it moves the story from a simple business failure to a calculated exploitation of the scientific process, where the rules of evidence were bent specifically to facilitate a capital raise.
Critics might argue that re-analyzing data is a standard part of scientific inquiry and that the company was simply optimistic. However, Legum counters this by showing that the re-analysis was timed perfectly to precede a record-breaking IPO, and the original trial had already been deemed a failure by the drug's previous owner, GlaxoSmithKline. The timing suggests intent rather than mere optimism.
The Exit Strategy and the Public Cost
The narrative shifts from the laboratory to the stock market, where the financial engineering becomes as transparent as the data manipulation. Legum describes a corporate structure designed to insulate insiders from the very risks they were selling to the public. The author writes that Ramaswamy "spent the ensuing two years promoting the drug intepirdine as a possible breakthrough for the millions of Americans who have Alzheimer's disease," all while structuring the company to ensure his own wealth was protected.
Judd Legum writes, "One state retirement fund for teachers lost more than $1 million." This sentence anchors the abstract financial maneuvering in real human loss. The California State Teachers' Retirement System saw its investment plummet from over $1.2 million to just $68,000 in the wake of the stock crash. Legum contrasts this devastating loss for public employees with the estimated $260 million the founder extracted from the company's parent entity, Roivant Sciences.
The author highlights the mechanism of this exit: a private deal with SoftBank that allowed insiders to cash out weeks before the final clinical trial failure became public knowledge. Legum notes that the company had "no revenue" and "no recruits for future clinical trials" at the time of the IPO, yet Ramaswamy told CNBC that the drug was "only one additional Phase 3 study away from approval." This discrepancy between the public pitch and the private reality is the heart of the piece's critique.
"Heads I win and tails I also win, in terms of the outcomes of the trial."
This quote, attributed to political scientist David Niven by Legum, perfectly encapsulates the asymmetry of the situation. The insiders were positioned to profit regardless of the drug's efficacy, while public investors bore the full brunt of the failure. Legum's reporting suggests that the "pump and dump" dynamic was not accidental but structural, facilitated by a limited public float and the concentration of shares in the hands of a few insiders.
A counterargument worth considering is that biotech investing is inherently high-risk, and investors should have done their own due diligence. Yet, Legum's evidence of the data manipulation suggests that the risk was not just high, but artificially obscured. When the foundational data is cherry-picked, the investor's ability to assess risk is fundamentally compromised.
The Political Shadow
The final section of Legum's analysis connects these past business practices to the present political moment. The author observes that Ramaswamy, now a gubernatorial candidate, has largely avoided discussing the specifics of the Axovant saga, preferring to speak in vague terms about his "business success." Legum writes that the campaign has received "tens of millions in combined financial backing from fellow right-wing billionaires," raising questions about the source of the capital and the narrative of competence it supports.
Judd Legum writes, "One of the defining questions of the campaign will be, are Ohioans talking about this in October — are they aware of how well he did, and how poorly most other folks did on that Alzheimer's drug?" This question reframes the candidate's biography not as a testament to innovation, but as a case study in regulatory arbitrage. The author points out that Ramaswamy has maintained he is "proud" of his work, claiming that "there is probably nothing in a meaningful way we could've done differently." Legum juxtaposes this defense with the reality of the stock crash and the financial ruin of public pension funds.
The piece concludes by noting that the drug's failure was part of a broader pattern of failure in the Alzheimer's space, yet the specific mechanism of Axovant's rise and fall remains unique in its reliance on data manipulation. Legum's framing challenges the reader to consider whether a candidate who profited from obscuring scientific failure is fit to lead on issues of public health and economic security.
Bottom Line
Judd Legum's investigation is a masterclass in connecting technical financial and scientific details to a broader story of accountability, exposing how a failed drug was weaponized for private gain at the expense of public trust. The strongest part of the argument is the meticulous documentation of how specific statistical methods were used to invert failure into success, making the deception difficult to dismiss as mere business optimism. The piece's biggest vulnerability is its reliance on the assumption that voters will care about the granular details of clinical trial re-analysis, but the human cost to the teachers' retirement fund provides a compelling emotional anchor that transcends the technicalities. As the election approaches, the question Legum raises—about the transparency of the candidate's past wealth creation—will likely become a central fault line in the race.